MARKET

MESO

MESO

Mesoblast
NASDAQ
13.61
-0.61
-4.29%
After Hours: 13.93 +0.32 +2.35% 19:30 10/06 EDT
OPEN
13.90
PREV CLOSE
14.22
HIGH
13.90
LOW
13.58
VOLUME
404.69K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
13.05
MARKET CAP
1.77B
P/E (TTM)
-30.6463
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MESO last week (0928-1002)?
Weekly Report · 1d ago
Weekly Report: what happened at MESO last week (0921-0925)?
Weekly Report · 09/28 10:17
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS) and Mesoblast (MESO)
TipRanks · 09/25 15:40
Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil
Benzinga · 09/24 11:06
Weekly Report: what happened at MESO last week (0914-0918)?
Weekly Report · 09/21 10:17
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 09/20 18:57
Weekly Report: what happened at MESO last week (0907-0911)?
Weekly Report · 09/14 10:23
Weekly Report: what happened at MESO last week (0831-0904)?
Weekly Report · 09/07 10:16
More
About MESO
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.